KMT2A and leukemia: MM-589, another peptidomimetic WDR5 inhibitor (Ki <1 nM), has been shown to inhibit H3K4 HMT activity of MLL1 with an IC50 value of 12.7 nM and potently inhibits the growth of human leukemia cell lines containing MLL translocation at sub-micromolar concentrations, which is > 40 times superior to that of MM-401 [202].